Martin Billger

Affiliations

Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden. Electronic address: Martin.Billger@astrazeneca.com.

Publications (2)

A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozin.

Regulatory toxicology and pharmacology : RTP

Avec: Martin Billger , Jason Kirk , Jane Chang , Agathe Bédard , Bassem Attalla , Solomon Haile , Magnus Söderberg

A comprehensive analysis of liver safety across zibotentan oncology trials: knowledge of the past offers new perspectives on the present.

Expert opinion on drug safety

Avec: Anna Fettiplace , Sherri Matis-Mitchell , Oleksandr Molodetskyi , Malin Söderbergh , Jan Oscarsson , Min Lin , Srivathsa Ravikiran , Martin Billger , Philip Ambery

Réseau de co-auteurs

Jason Kirk 1 collaboration

Jane Chang 1 collaboration

Agathe Bédard 1 collaboration

Bassem Attalla 1 collaboration

Solomon Haile 1 collaboration

Magnus Söderberg 1 collaboration

Anna Fettiplace 1 collaboration

Sherri Matis-Mitchell 1 collaboration

Oleksandr Molodetskyi 1 collaboration

Malin Söderbergh 1 collaboration

Jan Oscarsson 1 collaboration

Min Lin 1 collaboration

Srivathsa Ravikiran 1 collaboration

Philip Ambery 1 collaboration